AI-Enabled Smart Drug Delivery Systems Inspired by Natural Bioactive Polysaccharides: From Microbiome Modulation to Personalized Healthcare Applications
Keywords:
smart drug delivery, artificial intelligence, polysaccharides, microbiome modulation, personalized medicine, system governance, sustainabilityAbstract
The convergence of artificial intelligence, materials science, and systems engineering is opening unprecedented opportunities for smart drug delivery platforms that leverage the unique properties of natural bioactive polysaccharides. These biopolymers offer inherent biocompatibility, programmable degradation, mucoadhesion, and prebiotic activity, making them ideal scaffolds for targeting the gut microbiome while simultaneously delivering therapeutic agents. However, translating such multifunctional carriers into clinically viable personalized interventions demands a comprehensive system-level rethinking of design, deployment, and governance. This paper presents an interdisciplinary analysis of AI-enabled smart drug delivery systems inspired by polysaccharide chemistry, with a focus on the interplay between carrier architecture, microbiome modulation, and patient-specific data streams. We examine how machine learning can guide the discovery and optimization of polysaccharide conjugates, predict host–microbiome–drug interactions, and orchestrate closed-loop sensing and release. The discussion extends to infrastructure requirements for integrating wearable sensors, edge computing, and cloud-based learning for real-time adaptation. We critically assess structural trade-offs involving latency, data sovereignty, model interpretability, and regulatory alignment. Through a systems lens, we address fairness, sustainability of polysaccharide sourcing, and the policy implications of deploying autonomous drug delivery devices across diverse populations. Case illustrations are drawn from emerging research on bioactive polysaccharides that influence metabolic and microbial phenotypes. The paper argues that realizing the full potential of such integrated platforms requires not only advances in AI and biomaterials but also robust governance frameworks that balance innovation with equity and safety, ultimately enabling truly personalized, microbiome-aware healthcare.
References
1. Chen, R., & Zhang, L. (2023). Machine learning-driven formulation design for polysaccharide-based nanocarriers. Advanced Drug Delivery Reviews, 192, 114–132. https://doi.org/10.1016/j.addr.2023.114832
2. Williams, K. J., & Patel, S. (2022). Polysaccharide nanoparticles for colon-targeted drug delivery: A comprehensive review. Journal of Controlled Release, 345, 502–523. https://doi.org/10.1016/j.jconrel.2022.03.019
3. Garcia, M. T., & O’Brien, P. (2021). The gut microbiome as a therapeutic target in metabolic disease. Nature Reviews Gastroenterology & Hepatology, 18(5), 289–305. https://doi.org/10.1038/s41575-021-00428-6
4. Lee, S. H., & Thompson, R. E. (2024). Ingestible sensors for real-time gastrointestinal monitoring: State of the art and challenges. Science Translational Medicine, 16(732), eadj3874. https://doi.org/10.1126/scitranslmed.adj3874
5. Rahman, A., & Müller, F. (2020). Edge computing for wearable health devices: Architectures and trade-offs. IEEE Internet of Things Journal, 7(10), 9342–9355. https://doi.org/10.1109/JIOT.2020.2994365
6. Kim, Y., & Delcour, J. A. (2022). Pectin as a prebiotic fiber and its interaction with the human gut microbiota. Comprehensive Reviews in Food Science and Food Safety, 21(3), 2288–2323. https://doi.org/10.1111/1541-4337.12925
7. Bergman, M., & Silvestre, M. P. (2021). Short-chain fatty acids and intestinal barrier function. Trends in Molecular Medicine, 27(3), 245–258. https://doi.org/10.1016/j.molmed.2020.12.004
8. Ho, T. C., & Chang, C. C. (2023). Chitosan-based hydrogels for mucoadhesive drug delivery: Mechanisms and clinical prospects. Biomaterials, 292, 121912. https://doi.org/10.1016/j.biomaterials.2022.121912
9. Kumar, A., & Dash, S. (2021). Natural polysaccharides in the regulation of metabolic syndrome: Mechanisms and therapeutic potential. Carbohydrate Polymers, 260, 117801. https://doi.org/10.1016/j.carbpol.2021.117801
10. Zhao K, et al. Phyllostachys nigra (Lodd ex Lindl) derived polysaccharide with enhanced glycolipid metabolism regulation and mice gut microbiome. Int J Biol Macromol. 2024;257:128588.
11. Oberdorfer, L., & Tran, H. M. (2022). Machine learning prediction of nanoparticle properties for drug delivery. ACS Nano, 16(8), 11784–11796. https://doi.org/10.1021/acsnano.2c03160
12. Abdulridha, A., & Greco, F. (2023). Deep generative models for de novo polymer design in biomedical applications. Nature Machine Intelligence, 5(2), 147–160. https://doi.org/10.1038/s42256-023-00618-4
13. Morrison, G. C., & Ioannidis, S. (2020). Explainable AI for drug delivery systems: A case study with attention-based neural networks. Journal of Biomedical Informatics, 108, 103490. https://doi.org/10.1016/j.jbi.2020.103490
14. Liu, S. (2025). Revolutionizing healthcare: The role of artificial intelligence in drug discovery and delivery. Journal of Angiotherapy, 9(1), 1-16.
15. Nadkarni, P. M., & Ohno-Machado, L. (2022). Interpretability in medical machine learning: Challenges and pathways. npj Digital Medicine, 5, 51. https://doi.org/10.1038/s41746-022-00589-z
16. Ahmad, I., & Park, J. (2021). Real-time deep learning inference on resource-constrained embedded devices for ingestible electronics. IEEE Transactions on Biomedical Circuits and Systems, 15(4), 765–775. https://doi.org/10.1109/TBCAS.2021.3094421
17. Li, T., & Sahu, A. K. (2020). Federated learning: Challenges, methods, and future directions. IEEE Signal Processing Magazine, 37(3), 50–60. https://doi.org/10.1109/MSP.2020.2975749
18. Magnusdottir, S., & Thiele, I. (2021). Generating genome-scale metabolic models of the human gut microbiome. Current Opinion in Biotechnology, 67, 81–87. https://doi.org/10.1016/j.copbio.2020.12.011
19. Kaye, J., & Whitley, E. A. (2022). The governance of genomic and microbiome data beyond GDPR. Nature Genetics, 54(9), 1280–1285. https://doi.org/10.1038/s41588-022-01158-8
20. U.S. Food and Drug Administration. (2021). Artificial intelligence and machine learning in software as a medical device. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device
21. Pasolli, E., & Asnicar, F. (2021). Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell, 184(5), 1241–1259. https://doi.org/10.1016/j.cell.2021.01.010
22. European Commission. (2022). Proposal for a regulation on ecodesign for sustainable products. https://environment.ec.europa.eu/publications/proposal-ecodesign-sustainable-products-regulation_en
23. Trivedi, P., & Singh, B. P. (2020). Edge computing and AI for real-time soil monitoring and controlled release in agriculture. Computers and Electronics in Agriculture, 178, 105736. https://doi.org/10.1016/j.compag.2020.105736
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Clinical and Translational Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
